A study of biomarkers that predict efficacy of or resistance to trastuzumab emtansine for patients with HER2-positive non-small cell lung cancer

Trial Profile

A study of biomarkers that predict efficacy of or resistance to trastuzumab emtansine for patients with HER2-positive non-small cell lung cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Trastuzumab emtansine (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 04 Dec 2017 Results published in the Journal of Thoracic Oncology
    • 18 Oct 2017 Results (n=15) presented at the 18th World Conference on Lung Cancer.
    • 18 Oct 2017 According to results presented at the 18th World Conference on Lung Cancer, study was early terminated due to the limited efficacy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top